Drug Dealin – Details, episodes & analysis

Podcast details

Technical and general information from the podcast's RSS feed.

Drug Dealin

Drug Dealin Pod

Science

Frequency: 1 episode/37d. Total Eps: 10

Ever wondered what's really happening behind the scenes in the biotech and pharmaceutical industry? Drug Dealin' pulls back the curtain. Co-hosts Shivu Sharma and Kenny Lalwani, two seasoned BioPharma professionals, offer unparalleled insider insights, dissecting the latest news, trends, and catalysts. Each episode features in-depth discussions and interviews with industry luminaries, giving you honest and unvarnished perspectives you won't find anywhere else.

Read moreCollapse

Site

RSS

Apple

Recent rankings

Latest chart positions across Apple Podcasts and Spotify rankings.

Apple Podcasts

🇫🇷 France - lifeSciences
15/06/2026
#96
🇫🇷 France - lifeSciences
14/06/2026
#90
🇫🇷 France - lifeSciences
13/06/2026
#81
🇫🇷 France - lifeSciences
12/06/2026
#69
🇫🇷 France - lifeSciences
11/06/2026
#56
🇫🇷 France - lifeSciences
10/06/2026
#50
🇫🇷 France - lifeSciences
09/06/2026
#44
🇫🇷 France - lifeSciences
08/06/2026
#36
🇫🇷 France - lifeSciences
07/06/2026
#33
🇫🇷 France - lifeSciences
05/06/2026
#19

Spotify

No recent rankings available

Shared links between episodes and podcasts

Links found in episode descriptions and other podcasts that share them.

See all

https://www.bigpharmasharma.com/
4 shares
https://www.bigpharmasharma.com/p/what-2025-holds-for-glp-1s-in-brain
2 shares
https://bigpharmasharma.substack.com/
1 share

https://www.linkedin.com/in/kennylalwani/
5 shares
https://www.linkedin.com/in/kennylalwani
1 share

https://www.nature.com/articles/s41392-024-01931-z
1 share

RSS feed quality and score

Technical evaluation of the podcast's RSS feed quality and structure.

See all

RSS feed quality

To improve

Score global : 33%

Publication history

Monthly episode publishing history over the past years.

Year

Latest published episodes

Recent episodes with titles, durations, and descriptions.

See all

Ep. 2: Predictions for Biopharma in 2025

Episode 2

Friday, January 31, 2025 • Duration 57:57

Kenny and Shivu each cook up three predictions for Biopharma in 2025

NOTE: This episode was recorded on January 10th, 2025

Have feedback for us? Leave a comment or email us at DrugDealinPod@gmail.com

Disclaimer: The views and opinions expressed in this podcast are for informational and educational purposes only. They are not intended as medical advice and should not be used as a substitute for professional medical judgment or guidance. Always consult a qualified healthcare provider with any questions you may have regarding a medical condition or treatment.

Read moreCollapse

Ep. 1: Do Pharma Companies Avoid Cures?

Episode 1

Friday, January 31, 2025 • Duration 01:13:48

In this episode, we unpack, examine, and debunk the public perception that drug companies intentionally do not pursue curative therapies, because it is financially less beneficial to them. We speak from our own experience working on curative therapies in Oncology and HCV, discuss how difficult it is to develop cures, the implications of curing a disease for drug companies, and how the industry can do a better job fostering trust with patients.

Have feedback for us? Feel free to leave a comment or send us an email at DrugDealinPod@gmail.com

Read moreCollapse

Ep. 0: Welcome to the Drug Dealin' Podcast!

Thursday, January 30, 2025 • Duration 21:49

What is Drug Dealin' going to be about? How are the Drug Dealin' hosts and should you listen to us? What type of content can you expect from this show?

Read moreCollapse

Ep 3: Rise of the Phoenix | Sujal Shah & CymaBay Therapeutics

Episode 3

Tuesday, March 11, 2025 • Duration 02:20:49

A conversation with biotech leader, Sujal Shah, former CEO of CymaBay Therapeutics about his company's story arc, leadership, resilience, and building a biotech company in the face of adversity.

Questions?: drugdealinpod@gmail.com

Connect with Shivu: https://linktr.ee/shivusharma

Check out Big Pharma Sharma: https://bigpharmasharma.substack.com/

Connect with Kenny: https://www.linkedin.com/in/kennylalwani/

00:00 Introduction to Biotech Leadership

03:00 Sujal Shah's Journey in Biotech

05:46 Leadership Philosophy and Team Dynamics

09:13 Navigating Challenges at CymaBay

11:48 The Development of seladelpar

15:07 Strategic Decisions in Drug Development

17:58 Clinical Trials and Regulatory Interactions

20:50 The NASH Study and Its Implications

47:10 Navigating Drug Development Challenges

49:07 The Patient-Centric Approach in Drug Development

51:56 Facing Clinical Setbacks and Organizational Resilience

53:36 Unexpected Findings and Immediate Reactions

Ep.4: Ozempic for the Brain, A New Era to Explain

Episode 4

Monday, May 19, 2025 • Duration 54:59

Summary: In this episode, Shivu and Kenny delve into the evolving landscape of GLP-1 drugs, particularly focusing on the recent advancements in oral formulations and their potential applications beyond diabetes and obesity, including CNS diseases and addiction. They discuss the challenges of adherence, the mechanisms of action, and the economic implications of these therapies, while also highlighting the importance of early intervention in treatment. The conversation emphasizes the promising future of GLP-1s in various therapeutic areas and the ongoing research that will shape their role in healthcare.

References:

Shivu's recent substack post discussing GLP-1s for CNS disease: https://www.bigpharmasharma.com/p/what-2025-holds-for-glp-1s-in-brain
GLP-1 Growth Graph: Zheng, Z., Zong, Y., Ma, Y. et al. Glucagon-like peptide-1 receptor: mechanisms and advances in therapy. Sig Transduct Target Ther 9, 234 (2024).

Contact us:

Questions?: drugdealinpod@gmail.com
Follow us on X: ⁠https://x.com/DrugDealinPod⁠
Follow Shivu : ⁠https://linktr.ee/shivusharma⁠
Subscribe to Shivu's newsletter: https://www.bigpharmasharma.com/

Follow Kenny: ⁠https://www.linkedin.com/in/kennylalwani/⁠

Ep. 5: How to Talk to Doctors | Feat. Joe McCann, Co-Founder/CEO of Slingshot Insights

Episode 5

Tuesday, July 1, 2025 • Duration 01:41:29

Summary:

In this episode we chat with Joe McCann, CEO of Slingshot Insights. Joe estimates he has done somewhere between 5-10K calls interviewing physicians. In today's episode we tap into his insights on how to get more out of your conversations with doctors. Joe opens up his expert playbook on how to prepare and conduct calls with doctors. We also discuss how these tips/tricks can be applied by the everyday person to get more out of your interactions with healthcare practitioners and ensure you are getting the best care possible.

PROMO CODE:

DD Pod listeners who sign up for a "Starter" membership at Sling Shot Insights can get their first month FREE by entering the promo code: drugdealinpod25 at checkout
Learn more about slingshot at: www.slingshotinsights.com

Contact Joe McCann:

Email: Joe@slingshotInsights.com
X: @JMac_SI

Contact us:

Questions?: ⁠drugdealinpod@gmail.com⁠
Follow us on X: ⁠⁠https://x.com/DrugDealinPod⁠⁠
Follow Shivu : ⁠⁠https://linktr.ee/shivusharma⁠⁠
Subscribe to Shivu's newsletter: ⁠https://www.bigpharmasharma.com/⁠

Follow Kenny: ⁠⁠https://www.linkedin.com/in/kennylalwani/⁠

Ep. 6: Should the FDA Be Independent?

Episode 6

Tuesday, September 9, 2025 • Duration 01:41:59

SUMMARY: In this episode, Shivu and Kenny discuss the recent developments surrounding Replimune and its interactions with the FDA. They explore the implications of leadership changes at the FDA, the importance of patient advocacy, and the challenges faced by small biotech companies in navigating the regulatory landscape. The conversation highlights the critical role of stability in drug approvals and the potential impact on patient care, particularly in oncology. They discuss the complexities of the FDA's role in drug development, the importance of confirmatory studies, and the impact of leadership changes on regulatory processes. They also talk about the historical evolution of the FDA, its commitment to patient safety, and the challenges it faces in maintaining consistency and transparency. The conversation culminates in a thought-provoking discussion on the potential benefits of an independent FDA, akin to the Federal Reserve, to enhance trust and efficacy in drug approvals.

DISCLAIMER: The views and opinions expressed in this podcast are for informational and educational purposes only. They are not intended as medical advice and should not be used as a substitute for professional medical judgment or guidance. Always consult a qualified healthcare provider with any questions you may have regarding a medical condition or treatment.

CHAPTERS:

00:00 The FDA's Independence and Scope

02:53 Timeline of Instability at the FDA

14:00 Impact of Instability on Drug Development

19:54 Case Study: RepliMune's Regulatory Journey

34:00 Navigating FDA Interactions and Accelerated Approvals

58:03 The Role of a Healthy FDA: History and Function

01:12:40 Organizational Culture and Stability in Regulatory Agencies

01:15:24 Navigating Institutional Changes at the FDA

01:18:45 The Importance of Consistency in Health Guidelines

Drug Dealin – Details, episodes & analysis

Podcast details

Recent rankings

Apple Podcasts

Spotify

Shared links between episodes and podcasts

RSS feed quality and score

Publication history

Latest published episodes

Related Shows Based on Content Similarities

Related Shows Based on Content Similarities

Apple Podcasts

Spotify

Drug Dealin – Details, episodes & analysis

Podcast details

Recent rankings

Apple Podcasts

Spotify

Shared links between episodes and podcasts

Other4

LinkedIn2

Nature1

RSS feed quality and score

Publication history

Latest published episodes

Similar podcasts and content

Related Shows Based on Content Similarities

Related Shows Based on Content Similarities

Other4

LinkedIn2

Nature1

Apple Podcasts

Spotify